< BACK

VANCOUVER, B.C., CANADA (February 13, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), is announcing today that the company has appointed Mr. Gary Thompson of Fort Thomas, Kentucky to the serve as its President and CEO.  Mr. Thompson has served as the President and CEO of the company’s US subsidiary, M Pharmaceutical USA Inc., since August 2nd 2016, a role he will continue to fill going forward.

Mr. Brian Keane, who has served as Interim President and CEO of the M Pharmaceutical Inc., will continue to advise the company in the capacity of Senior Business Consultant.

“This is a natural evolution of our company,” said Director, Dr. Christopher Andrews. “Gary Thompson delivers an intimate knowledge and understanding of our pipeline products, including C-103 and ToConceive, combined with the ambition and vision to lead all aspects of the M Pharma strategy as the company focuses on developing and commercializing innovative drug treatments and biomedical technologies applied to improving outcomes in the obesity and women’s health spaces,” added Dr. Andrews.

Gary A. Thompson has over 30 years of sales and management experience in Fortune 500 health care organizations and start up pharmaceutical companies. He has served as Vice President of sales for Cigna Healthcare managing billions of assets over his career. Most recently, he has had management and leadership roles at several start up ventures that have obtained patents for innovative technologies including ToConceive LLC., (510K FDA Clearance) in the women’s health and wellness space, and with C-103, reformulated orlistat, in the obesity space. He is a graduate of Northern Kentucky University, with a BS in Kinesiology. Gary is also a Chairman of the Board of Nehemiah Vision Ministries based in Chambrun, Haiti, a registered 501(c)(3) Non-Profit organization.

“The team, resources and pipeline that we have strategically developed at M-Pharmaceutical Inc. will allow us to establish a high profile position in the obesity and women’s health spaces,” said Mr. Thompson. “I am excited to contribute my leadership to the company in order to bring our drug treatments and biomedical technologies to market with the aim of improving the quality of life for so many people,” added Mr. Thompson.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.  The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women’s health field.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company’s biomedical & drug technologies, and the acquisition of the rights to a new product.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

ABOUT CALLITAS

As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.

INVESTOR INQUIRIES

  • 1.859.868.3131
  • investors@callitas.com

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071

PRESS AND MEDIA INQUIRIES

  • pressroom@callitas.com

PRODUCT INQUIRIES